Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade
Ruth Plummer(National Health Service), Nagy Habib(Hammersmith Hospital), Jeffrey Yachnin(Karolinska University Hospital), Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Anthony B. El-Khoueiry(USC Norris Comprehensive Cancer Center), Bristi Basu(University of Cambridge), N Vasileiadou, Bríd M. Ryan(National Institutes of Health), Mélanie Grosso(Veracyte (United States)), CP Tan, Cheng Ean Chee(National University Cancer Institute, Singapore), John J. Rossi(City of Hope), Alison Adderkin, Nina Raulf(CTI BioPharma (United Kingdom)), Vikash Reebye(Imperial College London), Marcus Smith Noel(University of Rochester), Tim Meyer(The Royal Free Hospital), Mikael H. Sodergren(Imperial College London), J. Grimley Evans(Beatson West of Scotland Cancer Centre), Ilian Tchakov, Sarah P. Blagden(Churchill Hospital), Natalie Cook(The Christie NHS Foundation Trust), Aurélie Auguste(Veracyte (United States)), Maria Diab(Emory University), Iain A. McNeish(Imperial College London), Debashis Sarker(King's College - North Carolina), Dan Li(Beijing Anding Hospital), Kai‐Wen Huang(National Taiwan University Hospital), Joanna P. Nicholls(Imperial College London), Robert Habib(Society of Thoracic Surgeons), Denis Arnaud(Veracyte (United States)), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Jan Henrik Storkholm(Imperial College London), Rose Hodgson(University of Oxford)
Cited by 1
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k